Sagimet Biosciences Advances Acne Drug into Phase 3 Trials with $175M Financing — Sagimet Biosciences Inc.

Event summary

Sagimet Biosciences plans to initiate a Phase 3 clinical trial for denifanstat in moderate to severe acne patients in the second half of 2026.
The company secured $175 million in equity financing in April 2026, boosting its cash position to $257.6 million as of June 30, 2026.
Sagimet was added to the Russell 3000® and Russell 2000® indices effective June 29, 2026.
Phase 1 clinical trial of FASN inhibitor TVB-3567 is ongoing.

The big picture

Sagimet Biosciences is sharpening its focus on dermatology with the strategic advancement of denifanstat for moderate to severe acne. The $175 million financing and inclusion in key indices reflect growing investor confidence, but success hinges on the clinical trial outcomes and market differentiation. The biopharmaceutical sector continues to prioritize novel treatments for common conditions like acne, where chronic management presents significant revenue potential.

What we're watching

Clinical Progress: The pace at which denifanstat advances through Phase 3 trials will determine its potential approval timeline and market entry.
Financial Runway: Whether Sagimet's $257.6 million cash position can sustain operations through 2028, including the Phase 3 trial readout.
Competitive Positioning: How denifanstat's once-daily oral treatment option will compete in the acne market, which has not seen a new oral treatment in over forty years.